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Abstract
Background: Mebudipine, a dihydropyridine calcium-channel 
blocker (CCB), shows greater time- and voltage-dependent 
inhibitory effects than nifedipine. Its significant negative 
chronotropic effects without having considerable negative 
inotropic properties may make it a suitable candidate for the 
pharmacotherapy of heart failure (HF). This study aimed to 
investigate the possible beneficial action of mebudipine in a rat 
model of HF. 
Methods: The present study carried out in the Department of 
Pharmacology at the Iran University of Medical Sciences during the 
years of 2009-2011. An experimental model of HF was induced in 
male Wistar rats using doxorubicin (DOX). The rats were divided 
into five groups with seven animals in each group: normal control 
group, DOX-induced HF control groups, and treatment groups. 
The animals were administered DOX for 15 days. A consistent 
deterioration occurred after a four-week rest period. The animals 
were then treated with intraperitoneal mebudipine (0.5 mg/kg) 
and intraperitoneal amlodipine (0.35 mg/kg), as well as an equal 
volume of distilled water for 15 days. The plasma levels of big 
endothelin-1 (BET-1), creatine kinase-myocardial band (CK-
MB), lactate dehydrogenase (LDH), aspartate aminotransferase 
(AST), and alanine aminotransferase (ALT), as well as the clinical 
status (heart rate and blood pressure), were assessed before and 
after treatment.  Statistical analysis was performed with SPSS 
software using parametric and nonparametric ANOVA.
Results: Mebudipine and amlodipine reversed the increased 
plasma BET-1 values in the treated animals when compared 
with the HF control group (0.103 and 0.112 vs 0.231 pg/
mL, respectively). The increased plasma levels of AST, ALT, 
CK-MB, and LDH were also reversed in the HF animals that 
received mebudipine or amlodipine.
Conclusion: The administration of mebudipine to HF animals, 
akin to amlodipine, palliated the clinical and biochemical signs 
of the disease in the present study.
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What’s Known
• Among calcium-channel blockers, 
dihydropyridines are extensively used 
due to their potent vasodilatory and 
weak cardiodepressant properties.
•  Mebudipine is a newly synthesized 
dihydropyridine calcium-channel blocker 
that has significant negative chronotropic 
effects but without considerable negative 
inotropic properties.
What’s New
• In an animal model, mebudipine 
reversed the increased plasma levels of 
biochemical markers, which act as the 
prognostic and diagnostic indicators of 
heart failure.
• Administration of mebudipine 
to animals with doxorubicin -induced 
heart failure palliated the clinical and 
biochemical signs of the disease.
Original Article
Introduction
Heart failure (HF) is a chronic condition that results from any 
structural or functional cardiac disorders, leading to reduced 
cardiac output.1, 2 
